Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms

Wei Sun · Zirong Li · Zhengcai Shi · Bailiang Wang · Fuqiang Gao · Yurun Yang · Wanshou Guo

Abstract

Objective To explore the correlation between post-severe acute respiratory symptom (SARS) patients with osteonecrosis, investigate the etiology of post-SARS osteonecrosis and select the sensitive molecular symbols for early diagnosis and distinguish the high-risk population.

Methods The studied subjects were divided into two groups. Sixty-two post-SARS patients with osteonecrosis were one group, and 52 age- and sex-matched healthy people were as normal controlled group. Empty stomach blood samples from cubital veins were collected from both groups. Plasminogen activator inhibitor (PAI) by means of enzyme-linked immunosorbent assay and PAI-1 4G/5G polymorphism was detected by polymerase chain reaction and solid phase oligonucleotide assay.

Results The blood agents of post-SARS patients changed obviously with 15.64 ± 13.85 U/ml while the control group 7.96 ± 4.27 U/ml; 4G/4G genotype for the PAI-1 polymorphism detected in post-SARS group was more than that of the control group, but had no statistical significance. The plasma PAI activity was related to homozygote 4G/4G genotype. This reveals that homozygote 4G/4G genotype may be a susceptible gene mark to Chinese osteonecrosis patients.

Conclusion Plasminogen activator inhibitor-1 is a sensitive blood symbol for screening high-risk susceptible population; 4G/4G PAI-1 genotype may be an etiological factor in osteonecrosis.

Keywords Osteonecrosis · SARS · Plasminogen activator inhibitor (PAI)

Introduction

Osteonecrosis (ON) is a condition that can be categorized as traumatic and non-traumatic. A non-traumatic ON may be associated with an excessive corticosteroid administration, alcohol abuse or hematologic abnormality, and characterized by young onset age (20–50 years) and multiple joints involvement. Among several pathogeneses of non-traumatic ON, the intravascular coagulation activated by various potential risk factors may be a common way that results in the intraosseous thrombosis and ON. Moreover, as reported in a number of publications [1–6, 7], the ON is associated with an individual’s hyper-coagulable/hypo-fibrinolytic status, and plasminogen activator inhibitor (PAI) and corresponding gene polymorphism 4G/5G play an important role in the arterial or venous thrombosis [8].

In the spring of 2003, severe acute respiratory syndrome (SARS, a virus-induced disease) was prevalent in Beijing, the capital city of China. After a comprehensive investigation into the osteoarticular complication experienced by the patients recovered from the disease, it can be estimated that approximately 30 percent of these patients may suffer from multiple articular and/or diaphyseal necroses, but the remainders (approximately 70 %) who were infected with the same type of pathogens and treated with the same corticosteroid regimen were free from this complication [9]. Our previous study had revealed that hyper-coagulation and hypo-fibrinolysis were found in patients with post-
SARS ON [10, 11]. In the present study, the PAI and corresponding gene polymorphism 4G/5G were further determined in order to address its potential association with the occurrence of ON, thus providing a theoretical basis for the early identification and intervention of this specific ON.

Materials and methods

Clinical data

From July 2003 to February 2004, a radiological investigation was performed in patients who were suffered from SARS in the spring of 2003, including a comprehensive evaluation to systemic joints (bilateral hips, knees, ankles, shoulders and wrists for some of the patients) using magnetic resonance imaging (MRI), computer tomography (CT) and radiography. The films were evaluated by qualified radiologists and orthopedists, respectively, and an agreement for the final diagnosis may be obtained by a cooperative discussion for the films resulting in discrepant opinions from the two independent professionals. A total of 61 patients identified with ON (25 men, 36 women) and aged 30.4 years (20–60 years) were included as the study population in the present study. The following baseline parameters were obtained for these patients: mean received corticosteroid 7,706.4 mg (1,200–30,000 mg), mean daily maximal dosage of corticosteroid 373.2 mg (80–1,020 mg), mean duration of the corticosteroid medication 40.8 days (14–105 days) and mean duration of pulse therapy with corticosteroid (80 mg/day) 30.1 days (9–67 days). The joints involve included femoral head (N = 50, 87 hips; unilateral 13, bilateral 37), knee (N = 35, 63 knees; unilateral 7, bilateral 28), shoulder (N = 15, 24 shoulders; unilateral 6, bilateral 9), wrist (N = 4, 7 wrists; unilateral 1, bilateral 3; the individual bone involvement: 7 scaphoid bones, 2 capital bones and 1 lunar bone). The shaft involvement alone was seen in one patient. A total of 52 healthy volunteers without SARS and no steroid therapy [22 men, 30 women; aged 35.1 years (15–61 years)] were included in the present study as the control.

Blood sampling and preparation

An aliquot of fasting blood sample (8 ml/per patient) was collected from the cubital veins after the diagnosis of ON and more than 6 months after stopping corticosteroid therapy, and dispensed into a vacuum tube (3 ml) containing sodium citrate solution (3.8%) and a EDTA-based tube (2 ml) with the anticoagulant/whole blood ratio at 1:1 (v:v). The blood sample and the anticoagulant in both the tubes were gently mixed well and centrifuged at 2,500 rpm at the room temperature for 15 min for the collection of the supernatant (plasma).

Plasma PAI determination

The plasma plasminogen activator inhibitor (PAI) was determined using ELISA without necessity to perform a dilution to the plasma sample. The calibration curve was examined, with the starting point (0%) calibrated with Owren–Koller buffer. The quality control was established during the determination of each parameter tested, and the readings were collected at 405 nm (vWF at 540 nm; D–D at 800 nm). All the procedures during the determination were performed automatically.

Whole blood DNA extraction

Nine-hundred microliter of 5× STMT (diluted in sterile double distilled water at a ratio of 1:4 (v:v)) was added into 300 µl of EDTA-anticoagulated whole blood, gently mixed well, stood on ice for 10 min and centrifuged at 8,500 rpm for 30 s to remove the supernatant. After added with 300 µl of guanidinium isothiocyanate (5 N), the resulted white precipitate was gently shaken, added with 10 µl of Rnase A and stood at room temperature for 10 min. The product was added with 800 µl of 4 N NaClO4 (pH 5.2) and 20 µl resin (mixed sufficiently immediately before use), stood at room temperature for 5 min and centrifuged at 8,500 rpm for 30 s to remove the supernatant. The precipitate was then added with 500 µl washing buffer and centrifuged at 8,500 rpm for 30 s to remove the supernatant. The procedure was performed twice. The product was centrifuged at 12,000 rpm for 60 s, pipetting out the remaining liquid, stood at room temperature for 5 min, added with 100 µl of TE buffer, incubated at 50 °C for 10 min, centrifuged at 12,000 rpm for 60 s to remove the supernatant. The resulted precipitate was DNA.

Amplification, hybridization, labeling and determination of PAI-1 gene

The amplification, hybridization, labeling and determination of PAI-1 gene were performed using PCR and solid phase oligonucleotide assay (SPOLA).

Amplification

Eleven microliter of PCR mix (containing PAI-1 ampli-mix, primers and H2O), 5 µl of sample DNA, 1 µl of SYBER Green I and negative control (5 µl of H2O) were added into each of the LightCycler capillaries using a transferpettor and placed on a Roche PCR disc. The procedure established on
the LightCycler for the experiment was as follows: 94 °C 90 s → 94 °C 15 s → 63 °C 5 s → 72 °C 15 s × 35 cycles. The products were stored at 4 °C.

**Hybridization**

The test sample in each capillary subject to centrifugation was added with 5 μl of hybridization solution (containing PAI-1 probe, buffer and H2O), 10 μl for the mutation control and normal control, respectively. After mixed well, each 5 μl of solution inside the capillary was transferred into the WT well and MUT well of the plate and then incubated at the room temperature for 15 min.

**Labeling**

One hundred microliter of labeling solution (containing ligase, buffer and H2O) was added into each of the wells and incubated at the room temperature for 15 min.

**Washing and determination**

After the solution in the wells was removed, the 100 μl of washing buffer was added and then removed as soon as the washing procedure was performed. The product in the wells was added with specific enzyme-conjugated antibody (100 μl), incubated at the room temperature for 15 min, washed twice, added with substance (100 μl), incubated at the room temperature for 30 min and added with stop buffer before determination.

**Result assessment**

The samples were measured for the OD value at the 405 nm in the microplate reader. Based on the equation $R = OD(\text{WT})/OD(\text{MUT})$, the normal control was calibrated and defined as $R \geq 2.68$ and mutation control as $R \leq 0.32$. The result can be defined as follows based on the magnitude of $R$: 5G/5G, $R \geq 2.68$; 4G/4G, $R \leq 0.32$ and 4G/5G, $0.39 \leq R \leq 1.58$.

**Statistical management**

All the data were represented as mean ± SD and tested for statistical significance using SAS6.12 and SPSS11.0 software package. In view of the non-normality of a majority of the data, the difference between the post-SARS ON group and the control group was evaluated using Wilcoxon nonparametric test. The difference on the PAI genotype and the corresponding PAI value between these two groups was analyzed using ANOVA. $P$ value <0.05 was considered to be statistically significant.

**Results**

The patients with post-SARS ON (PAI value: $15.64 \pm 13.85$ U/ml) exhibited a more significant hypo-fibrinolytic tendency than those in the control group ($7.96 \pm 4.27$ U/ml), and the genotype 4G/4G for PAI-1 in these patients was more frequent to see than those in the control groups, but without statistical significance. The patients with increased genotype 4G/4G were also prone to the increase in plasma PAI, indicating a potential correlation between the PAI gene and its plasma activity (detailed in Tables 1, 2). The PAI value relative to different genotypes in the control group did not show any significant difference (Fig. 1).

**Discussion**

In recent years, the association between ON and disorders in coagulation and fibrinolysis systems was become increasingly highlighted, and it was demonstrated in numerous studies that non-traumatic ON was closely related to the coagulation and fibrinolysis disorders [12, 13–14]. The intravascular coagulation-induced thrombosis in the subchondral microcirculation may result in intraosseous hypertension, reduced blood stream and osteocytic ischemia/hypoxia, consequently leading to the necrosis of bone cells. This theory was further supported by the study conducted by Starklint et al. [15], who found fibrin thrombi in the area with ON. Hyper-coagulable/hypo-fibrinolytic status can be inherent or acquired. As a result of excessive corticosteroid administration, patients with SARS may develop such hyper-coagulable/hypo-fibrinolytic status, attributable to the intraosseous thrombosis and resulted ON. Therapy...
with corticosteroid may provide for the recipients a prethrombotic stage which is a pathological state that may contribute to the thrombosis. In patients with previously existed hyper-coagulable/hypo-fibrinolytic status, corticosteroid therapy may be more risky in the formation of ON. This is called as second hit theory for ON [16, 17].

Fibrinolysis system comprises a series of actors, substrates, activators and inhibitors that participate in the conversion from plasminogen to active fibrinogenase and the subsequent action on the fibrin. The fibrinolysis is indeed a chain reaction catalyzed by a group of proteins, mainly functioning to immediately lyse the fibrin clot created locally and temporarily to prevent from thrombosis. Among these factors, plasminogen activator inhibitor (PAI), a member of serine proteinase inhibitors, mainly takes effect via the deactivation of the tissue plasminogen activator and presents with an increased activity in hyper-coagulable and thrombotic diseases. The correlation between fibrinolytic disorders and ON has been confirmed in many publications. Similar to the study by Glueck et al. [18, 19] in which the correlation between PAI and ON was established, this study reported that PAI polymorphism may be the causative factor of the ON. Paolo et al. [21] performed a determination to the PAI-1 gene in patients with ON developed posterior to the renal transplantation and revealed that the presence of 4G/4G was more frequent to see in this patient group than in the patients absent of ON, thus concluding that genotype 4G/4G can serve as an indicator for the ON posterior to the renal transplantation. Moreover, as reported by Asano et al. [22], a discrepancy between the races may be observed in this aspect since no correlation was found between PAI-1 gene polymorphism and Japanese with post-renal transplantation ON.

We found in the present study that allele 4G was more frequent to see in patients with post-SARS ON, but without significant difference possibly due to the limitation by small sample size and statistical method used. In the present study, the plasma PAI level was higher in patients with genotype 4G/4G than those with the other two genotypes, suggesting the correlation between the increased PAI level in ON and the genotype 4G/4G. This indicated that PAI may be a potential biomarker used for the screening of the predisposing factor of ON and that PAI genotype 4G/4G may be the genetic marker for ON in Chinese patients. In conclusion, PAI and PAI-1 genotype 4G/4G deserve an important value in the screening for the population highly susceptible to non-traumatic ON.

Conflict of interest The authors declare that they have no conflict of interest.

References

1. Jones LC, Hungerford DS (2007) The pathogenesis of osteonecrosis. Instr Course Lect 56:179–196
2. Glueck CJ, Glueck HI, Mieczkowski L et al (1993) Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiology cause of osteonecrosis? Thromb Haemost 69:460–465
3. Glueck CJ, Freiberg R, Glueck HI et al (1995) Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 48:213–220

4. Van Veldhuizen PJ, Neff J, Murphey MD et al (1993) Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 44:243–248

5. Zalavras CG, Vartholomatos G, Dokou E et al (2004) Genetic background of osteonecrosis: associated with thrombophilic mutations? Clin Orthop Relat Res 422:251–255

6. Kerachian MA, Sequin C, Harvey EJ (2009) Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 114:121–128

7. Glueck CJ, Freiberg R, Tracy T et al (1997) Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis. Clin Orthop Relat Res 334:43–56

8. Kim H, Cho C, Cho Y et al (2011) Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head. BMC Musculoskelet Disord 14:160

9. Li ZR, Sun W, Qu H, et al (2005) Clinical research of correlation between osteonecrosis and steroid. Zhonghua Wai Ke Za Zhi 15;43(16):1048–1053

10. Sun W, Li ZR, Shi ZC et al (2006) Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Int Orthop 30(3):143–146

11. Sun W, Wang BL, Liu BL et al (2010) Osteonecrosis in patients after severe acute respiratory syndrome (SARS): possible role of anticardiolipin antibodies. J Clin Rheumatol 16(2):61–63

12. Mont MA, Jones LC, Hungerford DS (2006) Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am 88:1117–1132

13. Jones LC, Mont MA, Le TB et al (2003) Procoagulants and osteonecrosis. J Rheumat 30(4):783–792

14. Glueck CJ, Freiberg RA, Wang P (2003) Role of thrombosis in osteonecrosis. Curr Hematol Rep (Current Science) 2:417–422

15. Starklint H, Lausten GS, Arnoldi CC (1995) Microvascular obstruction in avascular necrosis. Immunohistochimistry of 14 femoral heads. Acta Orthop Scand 66(1):9–12

16. Jones JP Jr (1992) Intravascular coagulation and osteonecrosis. Clin Orthop 277:41–53

17. Jones JP Jr (1993) Fat embolism, intravascular coagulation, and osteonecrosis. Clin Orthop 292:294–308

18. Glueck CJ, Freiberg R, Glueck HI (1994) Hypofibrinolysis: a common, major cause of osteonecrosis. Am J Hematol 45(2):156–166

19. Glueck CJ, Freiberg RA, Fontaine RN et al (2001) Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop 386:19–33

20. Glueck CJ, Fontaine RN, Grouppo R (1999) The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop 366(9):133–146

21. Paolo F, Verena S, Suzanne A (2002) Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treatment renal allograft recipients. Transplantation 74(8):1147–1152

22. Asano T, Takahashi KA, Fujioka M (2004) Relationship between postrenal transplant osteonecrosis of the femoral head and gene polymorphisms related to the coagulation and fibrinolytic systems in Japanese subjects. Transplantation 77(2):220–225